Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported robust financial performance in its 2020 10-K filing, with revenues reaching $8.5 billion and net income soaring to $3.5 billion, representing significant year-over-year growth. This strong financial result was primarily driven by the exceptional performance of its key products, EYLEA and Dupixent, which continue to show substantial net product sales. The company also made significant progress in its pipeline, with a notable mention of REGEN-COV receiving Emergency Use Authorization (EUA) for COVID-19 treatment, contributing to its revenue stream. Regeneron's commitment to scientific innovation is evident in its extensive clinical development programs across various therapeutic areas, including ophthalmology, immunology, inflammation, and oncology. Looking ahead, Regeneron is well-positioned due to its strong financial footing and a diversified product portfolio and pipeline. The company continues to invest heavily in research and development, aiming to bring new treatments to patients. Investors should note the ongoing collaborations with major pharmaceutical companies like Sanofi and Bayer, which are crucial for global commercialization and revenue sharing. Despite the positive outlook, the company faces inherent risks associated with drug development, regulatory approvals, market competition, and the ongoing impact of the COVID-19 pandemic, all of which are detailed in the risk factors section.
Financial Highlights
48 data points| Revenue | $8.50B |
| R&D Expenses | $2.65B |
| SG&A Expenses | $1.35B |
| Operating Expenses | $4.92B |
| Operating Income | $3.58B |
| Interest Expense | $56.90M |
| Net Income | $3.51B |
| EPS (Basic) | $32.65 |
| EPS (Diluted) | $30.52 |
| Shares Outstanding (Basic) | 107.60M |
| Shares Outstanding (Diluted) | 115.10M |
Key Highlights
- 1Revenue surged to $8.5 billion in 2020, a substantial increase from $6.56 billion in 2019, demonstrating strong commercial execution.
- 2Net income reached $3.51 billion in 2020, a significant jump from $2.12 billion in 2019, reflecting improved profitability.
- 3EYLEA and Dupixent continue to be major revenue drivers, with U.S. EYLEA sales alone reaching $4.95 billion, highlighting the strength of Regeneron's established products.
- 4REGEN-COV, the company's antibody cocktail for COVID-19, received Emergency Use Authorization (EUA) in November 2020 and contributed $185.7 million in net product sales, showcasing rapid response to global health needs.
- 5Regeneron's extensive pipeline includes numerous product candidates in various stages of clinical development, indicating a strong commitment to future growth and innovation.
- 6The company actively manages its collaborations with Sanofi and Bayer, which are critical for the global commercialization and revenue generation of key products like Dupixent and EYLEA.
- 7Despite strong financial performance, Regeneron faces risks related to R&D uncertainties, market competition, regulatory hurdles, and the ongoing impact of the COVID-19 pandemic.